Dividends Inside 
Johnson & Johnson
JNJ
$263.04 (+ $9.06 + 3.57%)
Last updated: 2026-07-04 03:20 UTC
Johnson & Johnson trades under ticker JNJ on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US4781601046, CUSIP 478160104.
About the Company
Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, which focuses on pharmaceuticals including treatments for immunology, oncology, infectious diseases, neuroscience, cardiovascular and metabolic disorders, and pulmonary hypertension; and MedTech, which provides advanced surgical equipment, devices for orthopaedics, vision care, and solutions for robotics, navigation, and digital technologies. The company delivers innovative medicines and medical technologies that address unmet patient needs across diverse therapeutic areas, supporting healthcare professionals and consumers globally. Johnson & Johnson plays a pivotal role in the healthcare sector by advancing medical innovation and improving health outcomes through its broad portfolio of branded products and services. Founded in 1887 and headquartered in New Brunswick, New Jersey, it remains a cornerstone of the global health technology and pharmaceuticals industry.
Price History
Latest News for JNJ
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
MOUNTAIN VIEW, Calif., May 15, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributions to biomed
TREMFYA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
TREMFYA's market opportunities lie in its strong clinical efficacy, disease-modifying potential, and favorable safety profile across psoriasis and psoriatic arthritis. With broad label expansion into inflammatory conditions like IBD, its differentiated IL-23 inhibitor mechanism supports potential growth, especially in emerging markets.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "TREMFYA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The repo
How The Story For Johnson & Johnson (JNJ) Is Shifting With New Drugs And Legal Twists
The intrinsic value estimate for Johnson & Johnson has shifted slightly, with the fair value moving from US$252.42 to US$252.96 per share, a change of about 0.2%. That subtle move lines up with recent analyst research that focuses on execution around drugs like Icotyde, Inlexzo, Tecvayli and Tremfya, as well as on how the pipeline and broader healthcare positioning are shaping sentiment. As you read on, you will see how these price target tweaks fit into the wider story and what to watch as...
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient organizations—reveals the physical, mental, and emotional toll associated with standard-of-care therapies for bladder cancer, including surgery to remove the bladder and Bacillus Calmette-Guérin (BCG) treatment. Released ahead of the American Urological Association (AUA) Annual Meeting, the findings highlight patient experiences that may not alway
Jim Cramer on CoreWeave: “A Stock That’s Not for the Squeamish”
CoreWeave, Inc. (NASDAQ:CRWV) was among the stocks on Jim Cramer’s radar as he highlighted the importance of lower interest rates in sustaining the broader market rally. Answering a caller’s query about the stock during the episode, Cramer said: Okay, now, I gotta tell you… CoreWeave is what I call a stock that’s not for the […]
Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.